Lu Tianshu, Wu Tongchuan, Zhong Hao, Li Xue, Zhang Yunsen, Yue Hao, Dai Yulin, Li Haifeng, Ouyang Defang
Institute of Applied Physics and Materials Engineering, University of Macau, Macau, 999078, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau, 999078, China.
Drug Deliv Transl Res. 2025 Feb;15(2):700-716. doi: 10.1007/s13346-024-01628-4. Epub 2024 Jun 24.
(20 S)-Ginsenoside Rh2 is a natural saponin derived from Panax ginseng Meyer (P. ginseng), which showed significantly potent anticancer properties. However, its low water solubility and bioavailability strongly restrict its pharmaceutical applications. The aim of current research is to develop a modified (20 S)-Ginsenoside Rh2 formulation with high solubility, dissolution rate and bioavailability by combined computational and experimental methodology. The "PharmSD" model was employed to predict the optimal polymer for (20 S)-Ginsenoside Rh2 solid dispersion formulations. The solubility of (20 S)-Ginsenoside Rh2 in various polymers was assessed, and the optimal ternary solid dispersion was evaluated across different dissolution mediums. Characterization techniques included the Powder X-ray diffraction (PXRD) and Fourier transform infrared spectroscopy (FTIR). Molecular dynamics simulations were employed to elucidate the formation mechanism of the solid dispersion and the interactions among active pharmaceutical ingredient (API) and excipient molecules. Cell and animal experiments were conducted to evaluate the in vivo performance of the modified formulation. The "PharmSD" solid dispersion model identified Gelucire 44/14 as the most effective polymer for enhancing the dissolution rate of Rh2. Subsequent experiment also confirmed that Gelucire 44/14 outperformed the other selected polymers. Moreover, the addition of the third component, sodium dodecyl sulfate (SDS), in the ternary solid dispersion formulation significantly amplified dissolution rates than the binary systems. Characterization experiments revealed that the API existed in an amorphous state and interacted via hydrogen bonding with SDS and Gelucire. Moreover, molecular modeling results provided additional evidence of hydrogen bonding interactions between the API and excipient molecules within the optimal ternary solid dispersion. Cell experiments demonstrated efflux ratio (EfR) of Rh2 ternary solid dispersion was lower than that of pure Rh2. In vivo experiments revealed that the modified formulation substantially improved the absorption of Rh2 in rats. Our research successfully developed an optimal ternary solid dispersion for Rh2 with high solubility, dissolution rate and bioavailability by integrated computational and experimental tools. The combination of Artificial Intelligence (AI) technology and molecular dynamics simulation is a wise way to support the future formulation development.
(20 S)-人参皂苷Rh2是一种从人参(Panax ginseng Meyer)中提取的天然皂苷,具有显著的抗癌特性。然而,其低水溶性和生物利用度严重限制了其药物应用。当前研究的目的是通过计算和实验相结合的方法,开发一种具有高溶解度、溶出速率和生物利用度的改良(20 S)-人参皂苷Rh2制剂。采用“PharmSD”模型预测(20 S)-人参皂苷Rh2固体分散体制剂的最佳聚合物。评估了(20 S)-人参皂苷Rh2在各种聚合物中的溶解度,并在不同溶出介质中评估了最佳三元固体分散体。表征技术包括粉末X射线衍射(PXRD)和傅里叶变换红外光谱(FTIR)。采用分子动力学模拟来阐明固体分散体的形成机制以及活性药物成分(API)与辅料分子之间的相互作用。进行细胞和动物实验以评估改良制剂的体内性能。“PharmSD”固体分散体模型确定Gelucire 44/14是提高Rh2溶出速率最有效的聚合物。后续实验也证实Gelucire 44/14优于其他选定的聚合物。此外,在三元固体分散体制剂中添加第三组分十二烷基硫酸钠(SDS),其溶出速率比二元体系显著提高。表征实验表明,API以无定形状态存在,并通过氢键与SDS和Gelucire相互作用。此外,分子建模结果为最佳三元固体分散体内API与辅料分子之间的氢键相互作用提供了额外证据。细胞实验表明,Rh2三元固体分散体的外排率(EfR)低于纯Rh2。体内实验表明,改良制剂显著提高了大鼠体内Rh2的吸收。我们的研究通过综合计算和实验工具,成功开发了一种具有高溶解度、溶出速率和生物利用度的Rh2最佳三元固体分散体。人工智能(AI)技术与分子动力学模拟的结合是支持未来制剂开发的明智方法。